Marketing Efforts for Anti-psychotics Brings on Lawsuits
October 3rd, 2010 New York Times contains a long analysis of the problems in the marketing of antipsychotic drugs. These efforts have included ghost-writing medical journal articles, under-the-table...
View ArticleWhat’s Up with the FDA? Part 3
A new study finds that pioglitazone (trade name Actos tm), approved by the FDA for type 2 diabetes and an alternative to rosiglitazone trade name Avandia tm), causes significant weight gain- 3.9...
View Article
